Physician profile
Michael Lance Mitchell
NPI 1144953837
$4,465.11
in general payments reported to CMS, 2019-2025
31 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $252 · 2023: $1,680 · 2024: $1,458 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,114 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,113.63 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $663.36 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $567.23 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $472.74 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $410.82 | 2023-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $409.71 | 2022-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Novo Nordisk INC | $365.72 | 2022-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $269.88 | 2023-2025 | |
| Abbvie INC. | $264.34 | 2023-2025 | |
| Abbott Laboratories | $165.26 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $145.81 | 2022-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $132.33 | 2022-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $90.48 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.71 | 2024-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $46.05 | 2022 | |
| Merck Sharp & Dohme LLC | $44.82 | 2022-2023 | Belsomra, Steglatro, Steglujan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $37.33 | 2024-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $30.89 | 2022-2023 | |
| Radius Health, INC. | $30.29 | 2025 | Tymlos |
| Exact Sciences Corporation | $28.94 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Antares Pharma, INC. | $28.02 | 2024 | Xyosted |
| Sage Therapeutics, LLC | $26.93 | 2025 | Zurzuvae |
| Novartis Pharmaceuticals Corporation | $25.20 | 2025 | |
| Hologic Sales and Service, LLC | $22.16 | 2024 | Thinprep 2000 Processor, Aptima |
| Edwards Lifesciences Corporation | $22.14 | 2023 | |
| Sanofi Pasteur INC. | $20.95 | 2023 | |
| Dynavax Technologies Corporation | $17.60 | 2023 | Heplisav-B |
| Amgen INC. | $15.04 | 2023 | Evenity, Prolia |
| Medtronic, INC. | $13.94 | 2023 | Intellis Adaptivestim |
| Axsome Therapeutics, INC. | $13.52 | 2025 | Symbravo |
| Shield Therapeutics INC | $13.20 | 2024 | |
| Phathom Pharmaceuticals, INC. | $11.70 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.